Search Within

Hira Abbas Rizvi

Formats
  1. Journal Article (65)
  2. Meeting Abstract (58)
Groups
  1. Department of Medicine (123)
  2. Solid Tumor Oncology Division (123)
  3. Thoracic Oncology (121)
  4. Hematology-Oncology Fellows (81)
  5. GSK Faculty (67)
  6. Weinberg Fellows (67)

More Groups

People
  1. Matthew Hellmann (97)
  2. Gregory Riely (42)
  3. Andrew Plodkowski (41)
  4. Charles Rudin (37)
  5. Mark Kris (34)
  6. Kathryn Arbour (32)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (8)
  4. 2022 (17)
  5. 2021 (23)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Journal of Thoracic Oncology (16)
  3. Annals of Oncology (12)
  4. Clinical Cancer Research (12)
  5. Cancer Research (10)
  6. Cancer Cell (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (37)
  2. American Association for Cancer Research (28)
  3. Elsevier Inc. (20)
  4. Oxford University Press (13)
  5. Cell Press (7)
  6. American Medical Association (4)

More Publishers

Results (123)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Early change of dNLR is correlated with outcomes in advanced NSCLC patients treated with immunotherapy
    Meeting Abstract

    Mezquita, L.; Preeshagul, I.; Auclin, E.; Saravia, D.; Hendriks, L.; Rizvi, H.; Planchard, D.; Park, W.; Nadal, E.; Ruffinelli, J. C.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Multifactorial model to predict response to PD-(L)1 blockade in patients with high PD-L1 metastatic non-small cell lung cancer
    Meeting Abstract

    Arbour, K.; Oprescu, M.; Hakim, J.; Rizvi, H.; Leiserson, M.; Ginsburg, M.; Plodkowski, A.; Sauter, J.; Preeshagul, I.; Gillett, S.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Journal Article

    Hastings, K.; Yu, H. A.; Wei, W.; Sanchez-Vega, F.; DeVeaux, M.; Choi, J.; Rizvi, H.; Lisberg, A.; Truini, A.; Lydon, C. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    Journal Article

    Aguilar, E. J.; Ricciuti, B.; Gainor, J. F.; Kehl, K. L.; Kravets, S.; Dahlberg, S.; Nishino, M.; Sholl, L. M.; Adeni, A.; Subegdjo, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Association of BAP1 alterations with malignant pleural mesothelioma treated with trimodality therapy
    Meeting Abstract

    Zauderer, M. G.; Rizvi, H.; DuBoff, M. A.; Adusumilli, P. S.; Rusch, V. W.; Sauter, J. L.; Ladanyi, M.; Rimner, A.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A. J.; Chan, J. M.; Rizvi, H.; Rekhtman, N.; Daneshbod, Y.; Kubota, D.; Chang, J. C.; Arcila, M. E.; Ladanyi, M.; Somwar, R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer
    Meeting Abstract

    Rizvi, H.; Bandlamudi, C.; Schoenfeld, A. J.; Sauter, J. L.; Arbour, K. C.; Beras, A.; Egger, J. V.; Ladanyi, M.; Donoghue, M.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer
    Meeting Abstract

    Lai, W. C. V.; Rizvi, H.; Egger, J. V.; Plodkowski, A. J.; Ginsberg, M. S.; Kris, M. G.; Beras, A.; Rekhtman, N.; Poirier, J. T.; Hellmann, M. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ml-RECIST: Machine learning to estimate RECIST in patients with NSCLC treated with PD-(L)1 blockade
    Meeting Abstract

    Arbour, K. C.; Tuan, L. A.; Rizvi, H.; Yala, A.; Hellmann, M. D.; Barzilay, R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%
    Meeting Abstract

    Jimenez Aguilar, E.; Ricciuti, B.; Gainor, J. F.; Nishino, M.; Adeni, A. E.; Subegdjo, S.; Khosrowjerdi, S.; Peterson, R.; Digumarthy, S.; Liu, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save